Research and Markets: EpiCast Report: Fabry Disease Market 2015 - Epidemiology Forecast to 2024

Research and Markets (http://www.researchandmarkets.com/research/f3cmp4/epicast_report) has announced the addition of the "EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024" report to their offering.

Fabry disease is a rare X-linked inherited disorder caused by the deficiency of lysosomal enzyme a-galactosidase A (Nagueh, 2003). Fabry disease causes glycolipids such as globotriaosylceramide to accumulate in the vascular endothelium of skin, nervous system, heart and kidneys leading to inflammation and fibrosis resulting in organ dysfunction (Zarate and Hopkins, 2008).

The organ dysfunction is regarded as the first clinical evidence of Fabry disease (Tsuboi et al., 2012). The symptoms of Fabry disease are typically severe in men, whereas women show variable range of symptoms with some being non symptomatic and others showing severe symptoms (Golfomitsos et al., 2012).

This report provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex.

To construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in the 7MM, The publisher epidemiologists used data available from Fabry Support & Information Group (FSIG) for the US and the EU markets, and the data available for Japan from a population-based study conducted in Japan along with data available from FSIG for Asia-Pacific.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Epidemiology

4 Appendix

For more information visit http://www.researchandmarkets.com/research/f3cmp4/epicast_report

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005167/en/